Literature DB >> 17289236

Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China.

Yu-Tao Xiang1, Yong-Zhen Weng, Chi-Ming Leung, Wai-Kwong Tang, Gabor Sandor Ungvari, Jozsef Gerevich.   

Abstract

To date, few studies have investigated prescription patterns of psychotropic drugs in Chinese patients with schizophrenia in general and outpatients in particular. This study examined the role that socio-demographic and clinical factors play in determining psychotropic drug prescriptions for schizophrenia outpatients in China. Two hundred and fifty-five and 250 clinically stable outpatients with schizophrenia were randomly selected and interviewed in Hong Kong (HK) and Beijing (BJ) respectively, using standardized assessment instruments. Prescriptions of psychotropic drugs for all 505 subjects were collected at the time of the assessment. The relationship between antipsychotic drug prescription patterns and a host of socio-demographic and clinical variables was analyzed and compared between the two study sites. Prescription patterns were quite different for the two ethnically homogenous and clinically very similar samples. In multiple logistic regression analyses, the use of depot antipsychotics (DA) and site (HK vs BJ) both significantly predicted antipsychotic polypharmacy (APP), while symptoms of anxiety, use of clozapine and APP and site predicted use of DA. Age, number of hospitalizations, site, and use of DA predicted use of clozapine. No significant differences were found between the quality of life domains of patients with respect to APP, DA, and clozapine. A complex web of economic and clinical factors and health policies plays an important role in determining psychotropic drug prescription practices for Chinese outpatients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289236     DOI: 10.1016/j.pnpbp.2007.01.013

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

1.  Evaluation of Defined Daily Dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization.

Authors:  Waleed M Sweileh; Jihad Bani Odeh; Naser Y Shraim; Sa'ed H Zyoud; Ansam F Sawalha; Samah W Al-Jabi
Journal:  Saudi Pharm J       Date:  2013-04-06       Impact factor: 4.330

2.  Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.

Authors:  Eric Hermes; Robert Rosenheck
Journal:  J Psychopharmacol       Date:  2012-04-19       Impact factor: 4.153

3.  Sleep Disturbances and Their Association With Quality of Life in Older Psychiatric Patients During the COVID-19 Pandemic.

Authors:  Xiuying Xu; Wen Li; Siyun Zou; Yulong Li; Huan Wang; Xiaona Yan; Xiangdong Du; Lan Zhang; Qinge Zhang; Teris Cheung; Gabor S Ungvari; Yu-Tao Xiang
Journal:  J Geriatr Psychiatry Neurol       Date:  2022-03       Impact factor: 2.680

4.  The prevalence of depressive and anxiety symptoms and their associations with quality of life among clinically stable older patients with psychiatric disorders during the COVID-19 pandemic.

Authors:  Wen Li; Na Zhao; Xiaona Yan; Siyun Zou; Huan Wang; Yulong Li; Xiuying Xu; Xiangdong Du; Lan Zhang; Qinge Zhang; Teris Cheung; Gabor S Ungvari; Chee H Ng; Yu-Tao Xiang
Journal:  Transl Psychiatry       Date:  2021-01-26       Impact factor: 6.222

5.  Network Analysis of Depression, Anxiety, Posttraumatic Stress Symptoms, Insomnia, Pain, and Fatigue in Clinically Stable Older Patients With Psychiatric Disorders During the COVID-19 Outbreak.

Authors:  Wen Li; Na Zhao; Xiaona Yan; Xiuying Xu; Siyun Zou; Huan Wang; Yulong Li; Xiangdong Du; Lan Zhang; Qinge Zhang; Teris Cheung; Gabor S Ungvari; Chee H Ng; Yu-Tao Xiang
Journal:  J Geriatr Psychiatry Neurol       Date:  2022-03       Impact factor: 2.680

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.